LGND News and Press, Ligand Pharmaceuticals Incorporated From 02/05/20

Ligand Pharmaceuticals (NASDAQ: LGND ) is scheduled to announce Q4 earnings results on Thursday, February 6th, after market close. The consensus EPS Estimate is $0.12 (-92.9% Y/Y) and the consensus Revenue Estimate is $25.3M (-57.5% Y/Y). Over the last 2 years, LGND  has beaten EP...

Partner Gilead Sciences’ Captisol ® -enabled remdesivir (GS-5734) highlighted in the New England Journal of Medicine for treating the first case of the 2019 novel coronavirus in the United States OmniAb ® antibody discovery platform may be used by partners for the disc...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

OmniAb technology to be accessed by Pandion for range of discovery programs Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand’s ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the confer...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential Corporate Directors list. “On behalf of the Ligand board of director...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse&#x...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it ranked in Deloitte’s Technology Fast 500 ™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25 th year. Ligan...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...